Lowest observed adverse effect level definition

Lowest observed adverse effect level or "LOAEL" means the lowest tested dose or concentration of a substance that resulted in an observed adverse effect in exposed test organisms when all higher doses or concentrations resulted in the same or more severe effects.
Sample 1Sample 2Sample 3
Lowest observed adverse effect level or “LOAEL” means the lowest concentration of a hazardous substance at which there is a statistically or biologically significant increase in the frequency or severity of an adverse effect between an exposed population and a control group.
Sample 1Sample 2Sample 3
Lowest observed adverse effect level or "LOAEL" means the low- est concentration of a hazardous substance at which there is a statis- tically or biologically significant increase in the frequency or se- verity of an adverse effect between an exposed population and a con- trol group.
Sample 1Sample 2Sample 3

Examples of Lowest observed adverse effect level in a sentence

  • Repeated dose toxicity - Lowest observed adverse effect level - 300 mg/kg Rat - male + female(ECHA) liver - Practical/human experience.

  • A clinical test for detecting lead in living humans LOAEL Lowest observed adverse effect level.

  • Margin of Exposure; NOAEL = No observed adverse effect level; and LOAEL = Lowest observed adverse effect level.

  • Lowest observed adverse effect level (LOAEL): The lowest administered dose at which a statistically significant adverse effect, relative to that of the control, has been observed.

  • Lowest observed adverse effect level In the risk assessment paradigm under the Comprehensive Environmental Response, Compensation, and Liability Act a risk quotient greater that 1.0 indicates potential for risk.

  • In other words, it is the tested dose that directly precedes the LOAEL.9 Lowest observed adverse effect level: minimum dose leading to an observed harmful effect.

  • Summarised toxic risk values for fluoride (Source: TERA (toxicology excellence for risk assessment)) Organization NameAgency for Toxic Substances Disease registry (ATSDR) **NOAEL = No observed adverse effect level; *LOAEL = Lowest observed adverse effect level.

  • The ADI concept has often been used as a tool in reaching risk management decisions with an equation as follows: Acceptable Daily Intake (ADI) = NOAEL (or LOAEL)/(UF*MF) (Eq. 1) NOAEL = No observed adverse effect level LOAEL = Lowest observed adverse effect level UF = uncertainty factor MF = modifying factor In this equation the NOAELs (or LOAELs) that are derived directly from toxicological studies, may be modified by both an UF and MF.

  • Lowest observed adverse effect level" or "LOAEL" means the lowest tested dose or concentration of a substance which results in an observed adverse effect in exposed test organisms when all higher doses or concentrations result in the same or more severe effects.

  • In this study the only relevant route of exposure is dermal exposure and thus Dtotal =Dder.The risk assessment is performed by calculating the Risk Characterisation Ratio (RCR) from the Derived No Effect Level (DNEL): RCR = Exposure (Dtotal )/DNELDNEL is calculated from NOAEL ( No observed adverse effect level) or LOAEL( Lowest observed adverse effect level) which are test data of a given effect for animals like rats or mice.


More Definitions of Lowest observed adverse effect level

Lowest observed adverse effect level or "LOAEL" means the low- est concentration of a hazardous substance at which there is a statis-
Sample 1
Lowest observed adverse effect level or "LOAEL" means the lowest concentration of a hazardous substance at which there is a statis- tically or biologically significant increase in the
Sample 1
Lowest observed adverse effect level or "LOAEL" means the lowest tested dose or concentration of a substance which results in an observed
Sample 1
Lowest observed adverse effect level or “LOAEL” means the lowest tested dose or concentration of a substance which results in an observed adverse effect in exposed test organisms when all higher doses or concentrations results in the same or more severe effects.
Sample 1

Related to Lowest observed adverse effect level

  • Company Material Adverse Effect means any material adverse change in, or material adverse effect on, the business, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole; provided, however, that any change or effect resulting from (i) the industries and markets in which the Company and its Subsidiaries operate, (ii) the United States or the global economy or (iii) the United States financial or securities markets shall be excluded from the determination of Company Material Adverse Effect, in the case of clauses (i), (ii) and (iii), to the extent they have not had, or would reasonably be expected not to have, a materially disproportionate effect on the Company and its Subsidiaries relative to other companies in the same industry as the Company; and provided further that any change or effect resulting from the following, shall not constitute, and shall not be considered in determining whether there has occurred, a Company Material Adverse Effect: (1) the execution or the announcement of this Agreement, (2) natural disasters, acts of war, terrorism or sabotage, military actions or the escalation thereof or other force majeure events, (3) changes in GAAP or changes in the interpretation of GAAP, or changes in the accounting rules and regulations of the SEC, (4) any enactment or other action required by Law, required by this Agreement or taken at the request of the Parent or the Purchaser, (5) any litigation brought or threatened by stockholders of either the Parent or the Company (whether on behalf of the Company, the Parent or otherwise) asserting allegations of breach of fiduciary duty relating to this Agreement or violations of securities Laws in connection with the Schedule 14D-9, the Proxy Statement, if any, and each other document required to be filed by the Company with the SEC or required to be distributed or otherwise disseminated to the Company Stockholders in connection with the Transactions (collectively, the “Company Disclosure Documents”), (6) any changes in Law or interpretations thereof (including any health reform statutes, rules or regulations or interpretations thereof), (7) any action required to comply with the rules and regulations of the SEC or the SEC comment process, in each case, in connection with any Company Disclosure Document, (8) any decrease in the market price or trading volume of Company Common Stock (but not the underlying cause of such decrease), (9) any failure by the Company to meet any projections, forecasts or revenue or earnings predictions, or any predictions or expectations of the Company or of any securities analysts (but not the underlying cause of such failure), or (10) any fluctuations in foreign currency exchange rates.

  • Target Material Adverse Effect means any change, effect, event or occurrence that, individually or in the aggregate, has had or would reasonably be expected to have a material adverse change in, or effect on: (a) the ability of Seller to perform its obligations under the Specified Purchase Agreement and to consummate the transactions contemplated thereby; or (b) the assets, liabilities, business, condition (financial or otherwise) or results of operations of the Transferred Entities, taken as a whole; provided that, for purposes of clause (b) above, any such change, effect, event or occurrence resulting from any of the following shall not be considered when determining whether a Target Material Adverse Effect has occurred: (i) general economic conditions affecting the economy or credit, capital and financial markets in the United States or elsewhere in the world, including changes in interest or exchange rates; (ii) any change in the industry in which the Business operates; (iii) any change in Laws or GAAP, or the enforcement or interpretation thereof; (iv) general political conditions, including hostilities, acts of war (whether declared or undeclared), sabotage, terrorism or military actions, or any escalation or worsening of any of the foregoing; (v) any change resulting from the negotiation, execution, announcement or consummation of the transactions contemplated by the Specified Purchase Agreement or the Ancillary Agreements, including any such change relating to the identity of, or facts and circumstances relating to, Buyers and including any actions taken or threatened by any Transferred Entity’s customers, suppliers, distributors, employees or other personnel or others having relationships with a Transferred Entity; (vi) any action taken by Buyers and any of their respective Affiliates, agents or representatives; (vii) any hurricane, flood, tornado, earthquake or other natural disaster or any other force majeure event; (viii) any actions required to be taken or omitted pursuant to the Specified Purchase Agreement or the Ancillary Agreements or taken with Buyers’ consent or not taken because Buyers withheld, delayed or conditioned its consent; or (ix) the failure of the Business to achieve any financial projections or forecasts or revenue or earnings predictions (it being understood that for purposes of this clause (viii), the changes or effects giving rise to such failure that are not otherwise excluded from the definition of “Target Material Adverse Effect” may be taken into account in determining whether there has been a Target Material Adverse Effect); (x) events or occurrences specifically disclosed in the Seller Disclosure Letter, solely as and to the extent so described therein, and in each case only taking into account supplements to the Seller Disclosure Letter which have been permitted and made to the Seller Disclosure Letter with Buyers’ acceptance in accordance with Section 4.15 of the Specified Purchase Agreement; or (xi) any adverse change in or effect on the Business of the Transferred Entities that is cured prior to the Closing; provided, however, that any change or effect referred to in clauses (i), (ii), (iii), (iv) or (vii) immediately above may be taken into account in determining whether a Target Material Adverse Effect has occurred or would reasonably be expected to occur to the extent that such change, effect, event or occurrence has a materially disproportionate effect on the Transferred Entities relative to other companies in the industries or markets in which the Transferred Entities operate. Capitalized terms used in this definition of “Target Material Adverse Effect” without definition shall have the meanings ascribed thereto in the Specified Purchase Agreement; provided, that any capitalized terms which are defined in both this Agreement and the Specified Purchase Agreement shall have the meanings ascribed thereto in the Specified Purchase Agreement.

  • Closing Date Material Adverse Effect means a “Material Adverse Effect” as defined in the Acquisition Agreement.

  • Purchaser Material Adverse Effect means any material and adverse effect on (i) the ability of a Purchaser to meet its obligations under the Basic Documents on a timely basis or (ii) the ability of a Purchaser to consummate the transactions under any Basic Document.

  • Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b).

  • Material Adverse Event means any event, occurrence or state of facts which has or could reasonably be expected to have a material adverse effect on the business, properties, assets, operations, condition (financial or otherwise) of the Company or any of its Subsidiaries.

  • Material Adverse Change means any material adverse change in the business, condition (financial or otherwise), operations, performance, properties or prospects of the Borrower or the Borrower and its Subsidiaries taken as a whole.